Spiralling Medical Costs: Why Canada Needs NICE Medicine

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Medical Research Ethics

Background:

• Healthcare spending in Canada, particularly for pharmaceuticals, has seen significant recent growth.
• Conflicts of interest (COIs) are prevalent in medical research and clinical practice guidelines, often introducing bias.
• Manufacturer-funded drug studies and biased marketing practices contribute to inflated drug costs.

Purpose of the Study:

• To analyze the causes of escalating drug costs in Canada.
• To propose policy interventions for regulatory agencies and healthcare practices.
• To introduce a new regulatory body focused on clinical and cost-effectiveness.

Main Methods:

• Review of factors contributing to high drug prices, including research bias and marketing strategies.
• Analysis of current regulatory frameworks for drug approval, marketing, and surveillance.
• Development of policy proposals for therapeutic substitution and value-based assessments.

Main Results:

• Conflicts of interest in drug research frequently lead to biased findings favoring the drug manufacturer.
• Inappropriate marketing and selective publication contribute to increased drug costs.
• Therapeutic substitution with lower-cost alternatives presents a significant opportunity for cost reduction.

Conclusions:

• Reforming regulatory agencies for drug approval, marketing, and post-marketing surveillance is crucial.
• Establishing a new agency to evaluate drug and device value based on clinical and cost-effectiveness is proposed.
• Implementing cost-effectiveness criteria for medical interventions and therapeutic substitution can control healthcare spending.